 STAMFORD, Conn., March 31, 2021 GLOBE NEWSWIRE -- Cara Therapeutics, Inc. Nasdaq: CARA, a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that the Company will host a virtual research and development RD event on April 7 from 1:00 p.m. to 3:00 p.m. ET. The virtual event will include a presentation and interactive QA session to explore Caras first-in-class KOR agonist, KORSUVATM difelikefalin, being investigated for the treatment of chronic pruritus in systemic, dermatological, and neurological indications. 